Abstracts of the 2nd Annual Scientific Meeting of the British Society for Haematology 3-5 April 2022, Hybrid Meeting

ABSTRACT

Content b Many patients with haematological cancers remain incompletely protected from SARS-CoV-2 following two doses of vaccine with Pfizer-BioNTech BNT162b2 nCoV-19 or ChAdOx1. There was no significant difference in anti-S antibody response to vaccination in patients treated with intensive or non-intensive AML therapy but significantly reduced anti-S antibody titres were present in patients who received venetoclax-based regimens compared to other therapies ( I n i = 20, median 158.5 U/ml [IQR 34.85-873] vs. I n i = 19 median 796 U/ml [IQR 132-2500] I p i = 0.04). BSH22-OR37 Wrong blood in tube errors A single centre closed-loop audit Emily McMullen SP 1,* sp , James Uprichard SP 2 sp , Kelly Feane SP 3 sp SP I 1 i sp I Foundation training, Kingston hospital NHS Foundation Trust, i SP I 2 i sp I Clinical Haematology, St. George's University Hospitals NHS Foundation Trust, i SP I 3 i sp I Clinical Haematology, St. George's University Hospitals NHS Foundation Trus, London, UK i B Content b Serious Hazards of Transfusion (SHOT) defines WBITs as events where either blood is taken from the wrong patient and labelled with the intended patient's details;or blood is taken from the intended patient but labelled with a different patient's details. [Extracted from the article] Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)